Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Christchurch, Canterbury, New Zealand Clinical Trials

A listing of Christchurch, Canterbury, New Zealand clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer

The purpose of this study is to determine safety and anti-tumor immune activation generated by TG02 and Granulocyte macrophage colony stimulating factor (GM-CSF), first as monotherapy (Part I), thereafter in combination with the checkpoint inhibitor pembrolizumab (Part II), in patients with locally recurrent rectal cancer scheduled to have surgery. Part ...

Phase

0.0 miles

Learn More »

Study of Safety Tolerability and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women

Assess the safety and tolerability of REGN2477 alone and combined with REGN1033 in health postmenopausal women. Effect of REGN2477 alone, REGN1033 alone and REGN2477+REGN1033 in combination on muscle and body composition. Measure amount of REGN2477 and REGN1033 in blood. Assess presence or absence of antibodies for REGN2477 or REGN1033.

Phase

0.0 miles

Learn More »

Pharmacokinetics of GS-9876 in Adults With Impaired Renal Function

The primary objective of this study is to evaluate the pharmacokinetics (PK) of GS-9876 in participants with impaired renal function relative to matched healthy controls. Participants in this study will be enrolled using an adaptive design that includes up to 3 enrolled cohorts. Based on safety and/or PK data in ...

Phase

0.0 miles

Learn More »

A Dose-escalation Study of ARX788 IV Administered in Subjects With Advanced Cancers With HER2 Expression

This is a 2-part, Phase 1 FIH study with Phase 1a designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) in subjects with metastatic cancers with a human epidermal growth factor receptor 2 (HER2) test result that is in situ hybridization (ISH) positive (+) or immunohistochemistry (IHC) ...

Phase

0.0 miles

Learn More »

Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

This is a first-in-human, Phase 1, open-label, multicenter, dose-escalation study of CK-301, a fully human monoclonal IgG1 antibody targeting PD-L1. The study will consist of 3 periods: Screening (up to 28 days), Treatment (28-day cycles), and Follow-up (up to 6 months). Following the dose escalation portion of the study, additional ...

Phase

0.0 miles

Learn More »

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

This study aims to compare the PK/PD of a single injection of investigational Medicinal Product (IMP) MSB11456, US licensed Actemra and EU approved RoActemra in healthy adult subjects.

Phase

0.0 miles

Learn More »

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

This is a Phase I, randomized, double-blind, single-dose, 3-arm parallel group study to compare the PK, and to evaluate the safety, tolerability and immunogenicity, of BAT1706, EU-Avastin and US-Avastin after a single IV infusion in healthy adult male subjects. A total of 129 healthy male subjects who meet the required ...

Phase

0.2 miles

Learn More »

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Subjects and Heart Failure Patients

This study is a randomized, placebo-controlled, double-blind, single day ascending dose (SDAD) study (Part A), a multiple daily ascending dose (MDAD) study (Part B), in healthy subjects, and a MDAD study (Part C) in heart failure patients. In Parts A and B of the study, healthy volunteers will receive AMG ...

Phase

0.2 miles

Learn More »

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents. Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types. In Part 2, the same participants ...

Phase

0.2 miles

Learn More »

Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer

This study will investigate three escalating doses of NOX66 in combination with palliative dose of radiation therapy to establish safety profile and / or obtain efficacy signals and to determine the optimal dose for future radiation therapy combination studies. The key hypotheses to be tested in this study are: That ...

Phase

1.64 miles

Learn More »